United Therapeutics is making headway in unlocking a new lung disease market for its drug Tyvaso (treprostinil) with a ...

More than three years after launching a new corporate structure, Novartis is still making changes to its organization. | More than three years after launching a new corporate structure, Novartis is ...

While a recent head-to-head trial of the obesity med heavyweights Wegovy and Zepbound favored the latter drug from Eli Lilly on weight loss, Novo Nordisk has now countered that result with ...

German generics maker Stada has settled on a buyout by CapVest Partners, putting an end to its previously reported IPO ambitions. | After musing a fall IPO just last week, Stada is instead being ...

In the heat of the CDK4/6 market showdown, Eli Lilly has notched an overall survival win to back Verzenio’s case against ...

China biotech RemeGen and its new U.S. partner Vor Bio are on a roll with their first-in-class autoimmune treatment ...

Indivior’s restructuring plan is taking shape with initial headcount reductions to help move toward a more simplified ...

Amid uncertainty over how the Trump administration would approach mRNA COVID-19 vaccines for the upcoming respiratory virus ...

As for why ClevelandDx has chosen to re-up the “PSA on PSA” campaign for three years running rather than launching an ...

A newly published report developed by a group of partners, including Sanofi, shines a light on the far-reaching impacts of ...

The drug rilzabrutinib, which is now approved as Wayrilz in immune thrombocytopenia (ITP), has been hailed (PDF) by Sanofi as a potential “multi-indication blockbuster” that could deliver 2 billion ...

Phreesia is bringing Sesame Street to the doctor’s office. The patient activation company has partnered with the nonprofit ...